Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B

Nephrology Dialysis Transplantation

Volumn 26, Issue 6, 2011, Pages 2037-2041

  Lampertico, Pietro ^a   Vigan, Mauro ^a   Facchetti, Floriana ^a   Invernizzi, Federica ^a   Aroldi, Adriana ^a   Lunghi, Giovanna ^a   Messa, Pier Giorgio ^a   Colombo, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

adefovir dipivoxil; hepatitis B virus; lamivudine resistance; renal transplantation

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; LAMIVUDINE; PHOSPHORUS; VIRUS DNA;

ADD ON THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT RECIPIENT; HEPATITIS B; HUMAN; KIDNEY GRAFT; MALE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN URINE LEVEL; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS REPLICATION;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; KIDNEY TRANSPLANTATION; LAMIVUDINE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 79958111465     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr174     Document Type: Article

References (27)

1. Fabrizi F, Dulai G, Dixit V et al. Lamivudine for the treatment of hepatitis B virus related liver disease after renal transplantation: meta-analysis of clinical trials. Transplantation 2004; 77: 859-864. (Pubitemid 38436824)
2. Rostaing L, Henry S, Cisterne JM et al. Efficacy and safety of lamivudine on replication of recurrent hepatitis B after cadaveric renal transplantation. Transplantation 1997; 64: 1624-1627. (Pubitemid 28047399)
3. Goffin E, Horsmans Y, Cornu C et al. Lamivudine inhibits hepatitis B virus replication in kidney graft recipients. Transplantation 1998; 66: 407-409. (Pubitemid 28390229)
4. Jung YO, Lee YS, Yang WS et al. Treatment of chronic hepatitis B with lamivudine in renal transplant recipients. Transplantation 1998; 66: 733-737. (Pubitemid 28460107)
5. Mouquet C, Bernard B, Poynard T et al. Chronic hepatitis B treatment with lamivudine in kidney transplant patients. Transplant Proc 2000; 32: 2762. (Pubitemid 32008227)
6. Fontaine H, Thiers V, Chrétien Y et al. HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients. Transplantation 2000; 69: 2090-2094. (Pubitemid 30395039)
7. Kletzmayr J,Watschinger B, Müller C et al. Twelve months of lamivudine treatment for chronic hepatitis B virus infection in renal transplant recipients. Transplantation 2000; 70: 1404-1407.
8. Tsang WK, Tong KL, Chan HWH. Lamivudine therapy in renal allograft recipients with hepatitis B virus infection. Transplant Proc 2003; 35: 278-279. (Pubitemid 36194605)
9. Viganò M, Colombo M, Aroldi A et al. Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis. Antivir Ther 2005; 10: 709-713. (Pubitemid 41376849)
10. de Silva HJ, Herath CA, Sheriff MH. Lamivudine therapy for hepatitis B infection in post-renal transplant patients: results after 36 months follow-up. Liver Int 2005; 25: 1074-1075. (Pubitemid 41404032)
11. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539. (Pubitemid 46374607)
12. European Association For The Study Of The LiverEASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
13. Fontaine H, Vallet-Pichard A, Chaix ML et al. Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. Transplantation 2005; 80: 1086-1092. (Pubitemid 41611932)
14. de Silva HJ, Dassanayake AS, Manamperi A et al. Treatment of lamivudine- resistant hepatitis B infection in post-renal transplant patients with adefovir dipivoxil: preliminary results. Transplant Proc 2006; 38: 3118-3120. (Pubitemid 44737983)
15. Kamar N, Huart A, Tack I et al. Renal side effects of adefovir in hepatitis B virus-(HBV) positive kidney allograft recipients. Clin Nephrol 2009; 71: 36-42.
16. Tse KC, Yap DY, Tang CS et al. Response to adefovir or entecavir in renal allograft recipients with hepatitic flare due to lamivudine-resistant hepatitis B. Clin Transplant 2010; 24: 207-212.
17. Izzedine H, Hulot JS, Launay-Vacher V et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int 2004; 66: 1153-1158. (Pubitemid 39121022)
18. Izzedine H, Kheder-Elfekih R, Housset P et al. Adefovir dipivoxilinduced acute tubular necrosis and Fanconi syndrome in a renal transplant patient. AIDS 2009; 23: 544-545.
19. Tamori A, Enomoto M, Kobayashi S et al. Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus. J Viral Hepat 2010; 17: 123-129.
20. Gilead Science I. Hepsera (adefovir dipivoxil) Package Insert. 2008.
21. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
22. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470. (Pubitemid 29135798)
23. van Bömmel F, Zöllner B, Sarrazin C et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV-DNA level during adefovir therapy. Hepatology 2006; 44: 318-325. (Pubitemid 44214870)
24. Tanji N, Tanji K, Kambham N et al. Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol 2001; 32: 734-740. (Pubitemid 32726898)
25. Miller DS. Nucleoside phosphonate interactions with multiple organic anion transporters in renal proximal tubule. J Pharmacol Exp Ther 2001; 299: 567-574. (Pubitemid 32979669)
26. Izzedine H, Launay-Vacher V, Deray G. Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 2005; 45: 804-817. (Pubitemid 43181039)
27. Kamar N, Milioto O, Alric L et al. Entecavir therapy for adefovirresistant hepatitis B virus infection in kidney and liver allograft recipients. Transplantation 2008; 86: 611-614